A multicenter, randomized, vehicle-controlled phase 2 study of blue light photodynamic therapy with aminolevulinic acid HCl 20% topical solution for the treatment of actinic keratoses on the upper extremities: The effect of occlusion during the drug incubation period

Journal of Drugs in Dermatology

Volumn 11, Issue 12, 2012, Pages 1483-1489

  Schmieder, George J ^a   Huang, Eugene Y ^b   Jarratt, Michael ^c  

^a Park Avenue Dermatology ^*  (United States)

^b Therapeutics Clinical Research   (United States)

^c DermResearch Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; PLACEBO;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; BLUE LIGHT; BURN; CELLULITIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INCUBATION PERIOD; DRUG SAFETY; DRY SKIN; FEMALE; FOREARM; HAND; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OCCLUSIVE DRESSING; PHASE 2 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL; SCALING; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; TIME;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AMINOLEVULINIC ACID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KERATOSIS, ACTINIC; LIGHT; OCCLUSIVE DRESSINGS; PHARMACEUTICAL SOLUTIONS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN; TREATMENT OUTCOME; UPPER EXTREMITY;

EID: 84871071814     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009;116(11):2523-2530.
2. Jonason AS, Kunala S, Price GJ, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci U S A. 1996;93(24):14205-14209.
3. Ståhl PL, Stranneheim H, Asplund A, Berglund L, Pontén F, Lundeberg J. Sun-induced nonsynonymous p53 mutations are extensively accumulated and tolerated in normal appearing human skin. J Invest Dermatol. 2011;131(2):504-508.
4. ALA Kerastick (aminolevulinic acid HCl) for topical solution, 20% [package insert]. Wilmington, MA: DUSA Pharmaceuticals; 2010.
5. Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol. 2004;140(1):41-46. (Pubitemid 38090269)
6. Tschen EH, Wong DS, Pariser DM, et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol. 2006;155(6):1262-1269. (Pubitemid 44730005)
7. Szeimies RM, Karrer S, Sauerwald A, Landthaler M. Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology. 1996;192(3):246-251. (Pubitemid 26139209)
8. Jeffes EW, McCullough JL, Weinstein GD, et al. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot doseranging study. Arch Dermatol. 1997;133(6):727-732. (Pubitemid 27263706)
9. Kurwa HA, Yong-Gee SA, Seed PT, Markey AC, Barlow RJ. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol. 1999;41(3 pt 1):414-418. (Pubitemid 29418508)
10. Sotiriou E, Apalla Z, Maliamani F, Zaparas N, Panagiotidou D, Ioannides D. Intraindividual, right-left comparison of topical 5-aminolevulinic acid and photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. J Eur Acad Dermatol Venereol. 2009;23(9):1061-1065.
11. Taub AF, Garretson CB. A randomized, blinded, bilateral intraindividual, vehicle- controlled trial of the use of photodynamic therapy with 5-aminolevulinic acid and blue light for the treatment of actinic keratoses of the upper extremities. J Drugs Dermatol. 2011;10(9):1049-1056.
12. Warren CB, Lohser S, Wene LC, Pogue BW, Bailin PL, Maytin EV. Noninvasive fluorescence monitoring of protoporphyrin IX production and clinical outcomes in actinic keratoses following short-contact application of 5-aminolevulinate. J Biomed Opt. 2010;15(5):051607.
13. Ehrig T, Cockerell C, Piacquadio D, Dromgoole S. Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation. Dermatol Surg. 2006;32(10):1261-1265. (Pubitemid 44569998)